**Supplemental Digital Content 1.** Demographics, clinical features and HIV status of children with culture-confirmed tuberculosis: 1 March 2013 to 28 February 2017 (n=587)

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Fully drug susceptible** **(n=509; %a)** | **Any drug resistance****(n=78; %a)** | **All forms****(n=587; %a)** |
| Male gender | 268 (52.7) | 36 (46.2) | 304 (51.8) |
| Median age (IQR) in months | 34 (14-84) | 31 (15.5-69) | 34 (14-82) |
| Previous TB medication >1 monthb(preventive or treatment) | 53 (10.4) | 18 (23.1) | 71 (12.1) |
| Known TB contact historyb | 259 (50.9) | 51 (65.4) | 310 (52.8) |
| Tuberculin skin test doneTuberculin skin test positive | 186 (36.5)144 (77.4) | 37 (47.4)27 (73.0) | 223 (38.0)171 (76.7) |
| Type of TB - Pulmonary TB only- Extrapulmonary TB only- Both | 209 (41.1)92 (18.1)208 (40.9) | 39 (50.0)6 (7.7)33 (42.3) | 248 (42.2)98 (16.7)241 (41.1) |
| Extrapulmonary TB types (may have >1 type)- Peripheral lymphadenopathy- Tuberculous meningitis/tuberculomas- Pleural effusion (large only)- Miliary TB- Osteoarticular TB- Abdominal TB- Pericardial effusion - Ear/mastoid TB- Other (cutaneous/ superficial abscesses) | 135 (26.5)63 (12.4)26 (5.1)57 (11.2)39 (7.7)66 (13.0)12 (2.4)12 (2.4)30 (5.9) | 13 (16.7)4 (5.1)7 (9.0)7 (9.0)5 (6.4)13 (16.7)1 (1.3)1 (1.3)3 (3.8) | 148 (25.2)67 (11.4)33 (5.6)64 (10.9)44 (7.5)79 (13.5) 13 (2.2)13 (2.2)33 (5.6) |
| HIV tested- HIV-positive (% of those tested) | 496 (97.4)61 (12.3) | 77 (98.7)13 (16.9) | 573 (97.6)74 (12.9) |
| On cART before TB diagnosisDocumented start of cART after TB diagnosisNo documented cART (2 deaths, 5 unknown)) | 30 (49.2)24 (39.3)7 (11.5) | 7 (53.8)6 (46.2)0 | 37 (50.0)30 (40.5)7 (9.5) |

a Unless otherwise indicated

b Previous TB treatment (OR 2.58, 95%CI 1.42-4.70) and known TB contact history (OR 1.82, 95%CI 1.11-3.03) were significantly different comparing any drug-resistant to drug-susceptible TB groups

TB: tuberculosis; IQR: inter-quartile range; HIV: human immunodeficiency virus; cART=combination antiretroviral therapy